Nanomedicine Approaches for Rheumatoid Arthritis (RA): Targeted Therapy and Controlled Drug Release
Abstract
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder characterized by persistent synovial inflammation, progressive cartilage degradation, bone erosion, and joint deformity, ultimately leading to functional disability and reduced quality of life. Despite significant advances in disease management, conventional therapeutic approaches, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, conventional disease-modifying antirheumatic drugs (DMARDs), biologic agents, and Janus kinase (JAK) inhibitors, are frequently associated with limited tissue specificity, poor pharmacokinetic profiles, systemic adverse effects, and variable patient responses. These limitations have driven the development of nanomedicine-based drug delivery systems that offer enhanced targeting capabilities, improved drug stability, prolonged circulation time, and controlled drug release at inflamed joints. This review comprehensively summarizes recent advances in nanomedicine approaches for rheumatoid arthritis, with particular emphasis on targeted therapy and controlled drug release strategies. The review discusses the design principles and therapeutic potential of various nanocarriers, including liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, nanostructured lipid carriers, polymeric micelles, metallic nanoparticles, mesoporous silica nanoparticles, hydrogels, and extracellular vesicle-based systems. It further explores passive and active targeting mechanisms, stimuli-responsive drug release platforms, and nanocarrier-mediated delivery of anti-inflammatory agents, biologics, nucleic acids, and emerging therapeutics. Recent preclinical and clinical developments demonstrating improved therapeutic efficacy, reduced systemic toxicity, enhanced bioavailability, and modulation of inflammatory pathways are critically evaluated. Furthermore, the review highlights current challenges related to biological barriers, long-term biosafety, large-scale manufacturing, regulatory approval, and clinical translation while discussing emerging trends such as biomimetic nanocarriers, artificial intelligence-assisted nanomedicine design, precision medicine, and multifunctional theranostic platforms. Overall, advanced nanomedicine represents a promising strategy for improving the safety, efficacy, and personalization of rheumatoid arthritis treatment and holds significant potential for transforming future clinical management of this debilitating autoimmune disease.
Keywords: Rheumatoid arthritis; Nanomedicine; Targeted drug delivery; Controlled drug release; Nanocarriers.
Keywords:
Rheumatoid arthritis, Nanomedicine, Targeted drug delivery, Controlled drug releaseDOI
https://doi.org/10.22270/jddt.v16i9.7990References
1. Huang J, Fu X, Zhang R, et al. snoRNA Snord3 promotes rheumatoid arthritis by epigenetic regulation of ESM1 in fibroblast-like synoviocytes in mice. Sci Trans Med. 2025;17(824):eadt5340. doi: 10.1126/scitranslmed.adt5340 [DOI] [PubMed] [Google Scholar]
2. Zhao Y, Song S, Wang D, et al. Nanozyme-reinforced hydrogel as a H2O2-driven oxygenerator for enhancing prosthetic interface osseointegration in rheumatoid arthritis therapy. Nat Commun. 2022;13(1):6758. doi: 10.1038/s41467-022-34481-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
3. Chen M, Wang Z, Chen H, Li J, Guo X, Zhou S. Biomimetic Nanoparticles Inhibit the HIF-1α/iNOS/NLRP3 Pathway to Alleviate Rheumatoid Arthritis. Nano Lett. 2025;25(10):3807–12. doi: 10.1021/acs.nanolett.4c05782 [DOI] [PubMed] [Google Scholar]
4. Wang N, Ma J, Song W, Zhao C. An injectable hydrogel to disrupt neutrophil extracellular traps for treating rheumatoid arthritis. Drug Delivery. 2023;30(1):2173332. doi: 10.1080/10717544.2023.2173332 [DOI] [PMC free article] [PubMed] [Google Scholar]
5. Sheng N, Song R, Ye Y, et al. Recent progress in nanomaterials for the detection of rheumatoid arthritis-related biomarkers: a clinical perspective. Nano Biomed Eng. 2026;18(1):100008. doi: 10.1016/j.nbe.2025.100008 [DOI] [Google Scholar]
6. Song Y, Milichko VA, Ding Z, et al. Double Cross-Linked Hydrogel for Intra-articular Injection as Modality for Macrophages Metabolic Reprogramming and Therapy of Rheumatoid Arthritis. Adv Funct Mater. 2025;35(32):2502880. doi: 10.1002/adfm.202502880 [DOI] [Google Scholar]
7. Zhang J, Wang C, Wu X, Shen Q, Du Y. Nanozyme-based therapeutic strategies for rheumatoid arthritis. J Control Release. 2025;377:716–734. doi: 10.1016/j.jconrel.2024.11.072 [DOI] [PubMed] [Google Scholar]
8. Singh R, Malhotra H, Jadhav K, et al. Intelligently Actuating Dual-Barrier Hyaluronic Acid-Functionalized Inflammation-Responsive Nanohydrogel for Targeted Rheumatoid Arthritis Therapy. ACS Appl Mater Interfaces. 2025;17(28):40012–40034. doi: 10.1021/acsami.5c06055 [DOI] [PubMed] [Google Scholar]
9. Lin Y, Yi O, Hu M, et al. Multifunctional nanoparticles of sinomenine hydrochloride for treat-to-target therapy of rheumatoid arthritis via modulation of proinflammatory cytokines. J Control Release. 2022;348:42–56. doi: 10.1016/j.jconrel.2022.05.016 [DOI] [PubMed] [Google Scholar]
10. An L, Li Z, Shi L, et al. Inflammation-Targeted Celastrol Nanodrug Attenuates Collagen-Induced Arthritis through NF-κB and Notch1 Pathways. Nano Letter. 2020;20(10):7728–7736. doi: 10.1021/acs.nanolett.0c03279 [DOI] [PubMed] [Google Scholar]
11. Li R, Ma Y, Hong J, Ding Y. Nanoengineered therapy aiming at the etiology of rheumatoid arthritis. Nano Today. 2022;42:101367. doi: 10.1016/j.nantod.2021.101367 [DOI] [Google Scholar]
12. Zhang W, Xu T, Chen Y, Zhang G, Song Y. Advanced application of metal nanoparticles in the diagnosis and treatment of rheumatoid arthritis. Polyoxometalates. 2025;4(1):9140082. doi: 10.26599/POM.2024.9140082 [DOI] [Google Scholar]
13. Qiang R, Huang H, Chen J, et al. Carbon Quantum Dots Derived from Herbal Medicine as Therapeutic Nanoagents for Rheumatoid Arthritis with Ultrahigh Lubrication and Anti-inflammation. ACS Appl Mater Interfaces. 2023;15(32):38653–38664. doi: 10.1021/acsami.3c06188 [DOI] [PubMed] [Google Scholar]
14. Li H, Jin X, Chu B, et al. Inflammation Targeting and Responsive Multifunctional Drug-Delivery Nanoplatforms for Combined Therapy of Rheumatoid Arthritis. Small. 2025;21(22):e2500113. doi: 10.1002/smll.202500113 [DOI] [PubMed] [Google Scholar]
15. Deng Y, Li B, Zheng H, et al. Multifunctional Prussian blue nanoparticles loading with Xuetongsu for efficient rheumatoid arthritis therapy through targeting inflammatory macrophages and osteoclasts. Asian J Pharm Sci. 2025;20(3):101037. doi: 10.1016/j.ajps.2025.101037 [DOI] [PMC free article] [PubMed] [Google Scholar]
16. Gong Y, Zhou Z, Dong M-J, Liu H, Huang J, Dong H. Cerium-vanadium nanozyme/DNAzyme system for rheumatoid arthritis therapy through reactive oxygen species scavenging and inflammation regulation. Cell Biomaterials. 2025;2(2):100190. doi: 10.1016/j.celbio.2025.100190 [DOI] [Google Scholar]
17. Xiao S, Huang S, Wang M, et al. Biocatalytic and Redox-Regulated Nanoarchitectures for Precision Inflammation and Immune Homeostasis Modulation to Combat Rheumatoid Arthritis. Adv Mater. 2025;37(33):2502147. doi: 10.1002/adma.202502147 [DOI] [PubMed] [Google Scholar]
18. Zeng L, Zhao B, Chen D, Xia C, He Q. GeSe Nanosheets-Mediated Local Sonocatalytic Immunosuppression of Rheumatoid Arthritis. Adv Funct Mater. 2025;35(35):2420195. doi: 10.1002/adfm.202420195 [DOI] [Google Scholar]
19. Wang Y, Wang J, Ma M, et al. Hyaluronic-Acid-Nanomedicine Hydrogel for Enhanced Treatment of Rheumatoid Arthritis by Mediating Macrophage-Synovial Fibroblast Cross-Talk. Biomater Res. 2024;28:0046. doi: 10.34133/bmr.0046 [DOI] [PMC free article] [PubMed] [Google Scholar]
20. Li Y, Wang X, Gao Y, et al. Hyaluronic acid-coated polypeptide nanogel enhances specific distribution and therapy of tacrolimus in rheumatoid arthritis. J Nanobiotechnol. 2024;22(1):547. doi: 10.1186/s12951-024-02784-y [DOI] [PMC free article] [PubMed] [Google Scholar]
21. Han R, Zhou D, Ji N, et al. Folic acid-modified ginger-derived extracellular vesicles for targeted treatment of rheumatoid arthritis by remodeling immune microenvironment via the PI3K-AKT pathway. J Nanobiotechnol. 2025;23(1):41. doi: 10.1186/s12951-025-03096-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
22. Hu C, Ma J, Chen X, et al. Microenvironment-driven transformable self-assembly nanoplatform enables spatiotemporal remodeling for rheumatoid arthritis therapy. Sci Adv. 2025;11(36):eadu5245. doi: 10.1126/sciadv.adu5245 [DOI] [PMC free article] [PubMed] [Google Scholar]
23. Tao S, Yu H, You T, et al. A Dual-Targeted Metal–Organic Framework Based Nanoplatform for the Treatment of Rheumatoid Arthritis by Restoring the Macrophage Niche. ACS Nano. 2023;17(14):13917–13937. doi: 10.1021/acsnano.3c03828 [DOI] [PubMed] [Google Scholar]
24. Yang L, Huang H, Zeng H, et al. Biomimetic chitosan nanoparticles with simultaneous water lubricant and anti-inflammatory. Carbohydr Polym. 2023;304:120503. doi: 10.1016/j.carbpol.2022.120503 [DOI] [PubMed] [Google Scholar]
25. Xue G, Jiang H, Song Z, et al. Dual Targeting Biomimetic Carrier-Free Nanosystems for Photo-Chemotherapy of Rheumatoid Arthritis via Macrophage Apoptosis and Re-Polarization. Adv Sci. 2025;12(10):2406877. doi: 10.1002/advs.202406877 [DOI] [PMC free article] [PubMed] [Google Scholar]
26. Cheng F, Su T, Liu Y, et al. Targeting Lymph Nodes for Systemic Immunosuppression Using Cell-Free-DNA-Scavenging And cGAS-Inhibiting Nanomedicine-In-Hydrogel for Rheumatoid Arthritis Immunotherapy. Adv Sci. 2023;10(26):e2302575. doi: 10.1002/advs.202302575 [DOI] [PMC free article] [PubMed] [Google Scholar]
27. Wu M, Xie D, Wang L, et al. Spatiotemporally targeted nanocapsules combined with mild photothermal therapy regulate the synovial microenvironment in rheumatoid arthritis. Bioact Mater. 2026;58:33–48. doi: 10.1016/j.bioactmat.2025.11.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
28. Ma M-W, He K-L, Zhou S, et al. Dual-Pronged Attack: biomimetic Multi-Functional MOFs for Rheumatoid Arthritis Therapy via Inhibiting Synovial Hyperplasia and Improving Immune Microenvironment. ACS Nano. 2025;19(29):26525–26541. doi: 10.1021/acsnano.5c04787 [DOI] [PubMed] [Google Scholar]
29. Xu H, Wang Y, Rong X, et al. Ingenious Synergy of a Pathology-Specific Biomimetic Multifunctional Nanoplatform for Targeted Therapy in Rheumatoid Arthritis. Small. 2024;20(10):2305197. doi: 10.1002/smll.202305197 [DOI] [PubMed] [Google Scholar]
30. Song X, Zheng Z, Ouyang S, et al. Biomimetic Epigallocatechin Gallate–Cerium Assemblies for the Treatment of Rheumatoid Arthritis. ACS Appl Mater Interfaces. 2023;15(28):33239–33249. doi: 10.1021/acsami.3c02768 [DOI] [PubMed] [Google Scholar]
31. Zhang X, Meng S, Xiao Y, et al. Biomimetic and microenvironment-adaptive nanoplatform potentiates photodynamic therapy of rheumatoid arthritis via H2S-Modulated oxygen metabolism. Biomaterials. 2026;329:123926. doi: 10.1016/j.biomaterials.2025.123926 [DOI] [PubMed] [Google Scholar]
32. Tang Z, Meng S, Yang X, et al. Neutrophil-Mimetic, ROS Responsive, and Oxygen Generating Nanovesicles for Targeted Interventions of Refractory Rheumatoid Arthritis. Small. 2024;20(20):2307379. doi: 10.1002/smll.202307379 [DOI] [PubMed] [Google Scholar]
33. Zhang Q, Dehaini D, Zhang Y, et al. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nature Nanotechnol. 2018;13(12):1182–1190. doi: 10.1038/s41565-018-0254-4 [DOI] [PubMed] [Google Scholar]
34. Su Y, Chen R, Wang B, et al. Erythrocyte membrane camouflaged celastrol and bilirubin self-assembly for rheumatoid arthritis immunotherapy based on STING inhibition and RONS clearance. J Nanobiotechnol. 2025;23(1):318. doi: 10.1186/s12951-025-03389-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
35. Liu Y, Rao P, Qian H, et al. Regulatory Fibroblast-Like Synoviocytes Cell Membrane Coated Nanoparticles: a Novel Targeted Therapy for Rheumatoid Arthritis. Adv Sci. 2023;10(4):2204998. doi: 10.1002/advs.202204998 [DOI] [PMC free article] [PubMed] [Google Scholar]
36. Gan J, Huang D, Che J, Zhao Y, Sun L. Biomimetic nanoparticles with cell-membrane camouflage for rheumatoid arthritis. Matter. 2024;7(3):794–825. doi: 10.1016/j.matt.2023.12.022 [DOI] [Google Scholar]
37. Wang X, Huang J, Zhang S, et al. Biocatalytic Nanoregulators Restore Joint Redox-Immune Homeostasis in Rheumatoid Arthritis. Adv Sci. 2026;13(10):e02894. doi: 10.1002/advs.202502894 [DOI] [PMC free article] [PubMed] [Google Scholar]
38. Yuan S, Chai Y, Xu J, et al. Engineering Efferocytosis-Mimicking Nanovesicles to Regulate Joint Anti-Inflammation and Peripheral Immunosuppression for Rheumatoid Arthritis Therapy. Adv Sci. 2024;11(28):2404198. doi: 10.1002/advs.202404198 [DOI] [PMC free article] [PubMed] [Google Scholar]
39. He H, Zhang Q, Zhang Y, et al. Injectable bioadhesive and lubricating hydrogel with polyphenol mediated single atom nanozyme for rheumatoid arthritis therapy. Nat Commun. 2025;16(1):2768. doi: 10.1038/s41467-025-58059-z [DOI] [PMC free article] [PubMed] [Google Scholar]
40. Tian J, Chen T, Huang B, et al. Inflammation specific environment activated methotrexate-loaded nanomedicine to treat rheumatoid arthritis by immune environment reconstruction. Acta Biomater. 2023;157:367–380. doi: 10.1016/j.actbio.2022.12.007 [DOI] [PubMed] [Google Scholar]
41. Guo C, Diao N, Zhang D, et al. Achyranthes polysaccharide based dual-responsive nano-delivery system for treatment of rheumatoid arthritis. Int J Biol Macromol. 2023;234:123677. doi: 10.1016/j.ijbiomac.2023.123677 [DOI] [PubMed] [Google Scholar]
42. Wang Q, Peng X, Gao X, et al. Peptide-Oligonucleotide Nanohybrids Designed for Precise Gene Therapy of Rheumatoid Arthritis. Adv Mater. 2025;37(18):2500883. doi: 10.1002/adma.202500883 [DOI] [PubMed] [Google Scholar]
43. Wang F, Han Y, Zhou Q, et al. Polymer-modified DNA hydrogels for living mitochondria and nanozyme delivery in the treatment of rheumatoid arthritis. Bioact Mater. 2025;47:448–459. doi: 10.1016/j.bioactmat.2024.12.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
44. Li B, Yang C, Guo M, et al. Ultrasound-Remote Selected Activation Mitophagy for Precise Treatment of Rheumatoid Arthritis by Two-Dimensional Piezoelectric Nanosheets. ACS Nano. 2023;17(1):621–635. doi: 10.1021/acsnano.2c09834 [DOI] [PubMed] [Google Scholar]
45. Zhang X, Fu X, Chen W, et al. Amelioration of the rheumatoid arthritis microenvironment using celastrol-loaded silver-modified ceria nanoparticles for enhanced treatment. J Nanobiotechnol. 2025;23(1):372. doi: 10.1186/s12951-025-03388-w [DOI] [PMC free article] [PubMed] [Google Scholar]
46. Kalashnikova I, Chung SJ, Nafiujjaman M, et al. Ceria-based nanotheranostic agent for rheumatoid arthritis. Theranostics. 2020;10(26):11863–11880. doi: 10.7150/thno.49069 [DOI] [PMC free article] [PubMed] [Google Scholar]
47. Dave P, Raval B, Dudhat K. Cubosomes: Next-generation nanocarriers for versatile drug delivery system for cancer therapy and other applications. Biomedical Materials & Devices. 2026 Jun;4(2):1819-50.
48. Jia M, Ren W, Liu Y, et al. Messenger Nanozyme for Reprogramming the Microenvironment of Rheumatoid Arthritis. ACS Appl Mater Interfaces. 2023;15(1):338–353. [DOI] [PubMed] [Google Scholar]
49. Xu C, Jiang Y, Wang H, et al. Arthritic Microenvironment Actuated Nanomotors for Active Rheumatoid Arthritis Therapy. Adv Sci. 2023;10(4):2204881. doi: 10.1002/advs.202204881 [DOI] [PMC free article] [PubMed] [Google Scholar]
50. Zhang H, Jia J, Liu H, Han H, Li Q. Near-infrared light-driven metabolic reprogramming of synoviocytes for the treatment of rheumatoid arthritis. Nat Commun. 2025;16(1):6590. doi: 10.1038/s41467-025-61923-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
51. Liu L, Li X, Wu Z, et al. Inflammation-Targeting Fullerene Nanoparticles Dually Inhibit Macrophage and Osteoclast Differentiation for Mitigating Rheumatoid Arthritis. Chin Chem Soc Chem. 2024;6(9):2275–2288. [Google Scholar]
52. Chen S, Liu X, Zhang W, et al. Nanozyme Coating-Mediated Mitochondrial Metabolic Reprogramming of Macrophages for Immunomodulatory Osseointegration in Rheumatoid Arthritis Case. ACS Nano. 2025;19(28):26127–26146. doi: 10.1021/acsnano.5c07535 [DOI] [PubMed] [Google Scholar]
53. Yang J, Yang B, Shi J. A Nanomedicine-Enabled Ion-Exchange Strategy for Enhancing Curcumin-Based Rheumatoid Arthritis Therapy. Angew Chem Int Ed. 2023;62(44):e202310061. doi: 10.1002/anie.202310061 [DOI] [PubMed] [Google Scholar]
54. Kim J, Kim HY, Song SY, et al. Synergistic Oxygen Generation and Reactive Oxygen Species Scavenging by Manganese Ferrite/Ceria Co-decorated Nanoparticles for Rheumatoid Arthritis Treatment. ACS Nano. 2019;13(3):3206–3217. doi: 10.1021/acsnano.8b08785 [DOI] [PubMed] [Google Scholar]
55. Ma H, Li X, Feng X, Li Y, Liu D, Han L. Mesoporous Silica-Based Nanomotors Loaded with Rapamycin for Synergistic Treatment of Rheumatoid Arthritis. ACS Nano. 2025;19(25):22914–22930. doi: 10.1021/acsnano.5c01763 [DOI] [PubMed] [Google Scholar]
56. Liu Y, Chen L, Chen Z, et al. Multifunctional Janus Nanoplatform for Efficiently Synergistic Theranostics of Rheumatoid Arthritis. ACS Nano. 2023;17(9):8167–8182. doi: 10.1021/acsnano.2c11777 [DOI] [PubMed] [Google Scholar]
57. Zhang Y, Kang X, Li J, et al. Inflammation-Responsive Nanoagents for Activatable Photoacoustic Molecular Imaging and Tandem Therapies in Rheumatoid Arthritis. ACS Nano. 2024;18(3):2231–2249. doi: 10.1021/acsnano.3c09870 [DOI] [PubMed] [Google Scholar]
58. Li L, Yin J, Ma W, et al. A DNA origami device spatially controls CD95 signalling to induce immune tolerance in rheumatoid arthritis. Nat Mater. 2024;23(7):993–1001. doi: 10.1038/s41563-024-01865-5 [DOI] [PubMed] [Google Scholar]
59. Brzezicka KA, Arlian BM, Wang S, Olmer M, Lotz M, Paulson JC. Suppression of Autoimmune Rheumatoid Arthritis with Hybrid Nanoparticles That Induce B and T Cell Tolerance to Self-Antigen. ACS Nano. 2022;16(12):20206–20221. doi: 10.1021/acsnano.2c05643 [DOI] [PubMed] [Google Scholar]
60. Wang R, Shi J, Zhang Q, et al. Dual-Triggered Near-Infrared Persistent Luminescence Nanoprobe for Autofluorescence-Free Imaging-Guided Precise Therapy of Rheumatoid Arthritis. Adv Sci. 2023;10(4):2205320. doi: 10.1002/advs.202205320 [DOI] [PMC free article] [PubMed] [Google Scholar]
61. Li S, Li -J-J, Zhao -Y-Y, et al. Supramolecular Integration of Multifunctional Nanomaterial by Mannose-Decorated Azocalixarene with Ginsenoside Rb1 for Synergistic Therapy of Rheumatoid Arthritis. ACS Nano. 2023;17(24):25468–25482. doi: 10.1021/acsnano.3c09140 [DOI] [PubMed] [Google Scholar]
62. Ma C, Li B, Zhang J, et al. Significantly Improving the Bioefficacy for Rheumatoid Arthritis with Supramolecular Nanoformulations. Adv Mater. 2021;33(16):e2100098. doi: 10.1002/adma.202100098 [DOI] [PubMed] [Google Scholar]
63. Zheng M, Jia H, Wang H, Liu L, He Z, Zhang Z, et al. Application of nanomaterials in the treatment of rheumatoid arthritis. RSC Adv. 2021;11(13):7129-37. [PubMed ID: 35423287]. [PubMed Central ID: PMC8695100]. https://doi.org/10.1039/d1ra00328c
64. Uke P, Maharaj A, Adebajo A. A review on the epidemiology of rheumatoid arthritis: An update and trends from current literature. Best Pract Res Clin Rheumatol. 2025;39(1):102036. [PubMed ID: 39939219]. https://doi.org/10.1016/j.berh.2025.102036.
65. Pachani RV, Shah TM, Soni D. Advances in peptide- and antibody-targeted nanocarriers for cancer therapy and imaging. J Popul Ther Clin Pharmacol. 2021;28(1):392–419. doi:10.53555/3sadmc24. Journal of Population Therapeutics
66. Hajiaghayi M, Dolati-Somarin AH, Gholizadeh F. The efficacy of evening primrose in rheumatoid arthritis: a systematic review. Research Journal of Pharmacognosy. 2024;11(2):71-9.
67. Oliveira IM, Gonçalves C, Reis RL, Oliveira JM. Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends. Nano Research. 2018;11(9):4489-506. https://doi.org/10.1007/s12274-018-2071-3.
68. Li H, Gou R, Liao J, Wang Y, Qu R, Tang Q, et al. Recent advances in nano-targeting drug delivery systems for rheumatoid arthritis treatment. Acta Materia Medica. 2023. https://doi.org/10.55415/deep-2023-0006.v1.
69. Jang S, Kwon EJ, Lee JJ. Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells. Int J Mol Sci. 2022;23(2). [PubMed ID: 35055087]. [PubMed Central ID: PMC8780115]. https://doi.org/10.3390/ijms23020905.
70. Li C, Han Y, Luo X, Qian C, Li Y, Su H, et al. Immunomodulatory nano-preparations for rheumatoid arthritis. Drug Deliv. 2023;30(1):9-19. [PubMed ID: 36482698]. [PubMed Central ID: PMC9744217]. https://doi.org/10.1080/10717544.2022.2152136
71. Janakiraman K, Krishnaswami V, Rajendran V, Natesan S, Kandasamy R. Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights. Mater Today Commun. 2018;17:200-13. [PubMed ID: 32289062]. [PubMed Central ID: PMC7104012]. https://doi.org/10.1016/j.mtcomm.2018.09.011.
72. Hsu PH, Almutairi A. Recent progress of redox-responsive polymeric nanomaterials for controlled release. J Mater Chem B. 2021;9(9):2179-88. [PubMed ID: 33616136]. https://doi.org/10.1039/d0tb02190c.
73. Lenders V, Koutsoumpou X, Sargsian A, Manshian BB. Biomedical nanomaterials for immunological applications: ongoing research and clinical trials. Nanoscale Adv. 2020;2(11):5046-89. [PubMed ID: 36132021]. [PubMed Central ID: PMC9418019]. https://doi.org/10.1039/d0na00478b.
74. Yang C, Li D, Teng D, Zhou Y, Zhang L, Zhong Z, et al. Epigenetic Regulation in the Pathogenesis of Rheumatoid Arthritis. Front Immunol. 2022;13:859400. [PubMed ID: 35401513]. [PubMed Central ID: PMC8989414]. https://doi.org/10.3389/fimmu.2022.859400.
75. Alivernini S, Firestein GS, McInnes IB. The pathogenesis of rheumatoid arthritis. Immunity. 2022;55(12):2255-70. [PubMed ID: 36516818]. https://doi.org/10.1016/j.immuni.2022.11.009.
76. Tu AB, Lewis JS. Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis. Drug Deliv Transl Res. 2021;11(6):2371-93. [PubMed ID: 34414564]. [PubMed Central ID: PMC8376117]. https://doi.org/10.1007/s13346-021-01038-w.
77. Wu H, Su S, Wu Y, Wu Y, Zhang Z, Chen Q. Nanoparticle-facilitated delivery of BAFF-R siRNA for B cell intervention and rheumatoid arthritis therapy. Int Immunopharmacol. 2020;88:106933. [PubMed ID: 32866781]. https://doi.org/10.1016/j.intimp.2020.106933.
78. Zamani B, Taghvaee F, Akbari H, Mohtashamian A, Sharifi N. Effects of Selenium Supplementation on the Indices of Disease Activity, Inflammation and Oxidative Stress in Patients with Rheumatoid Arthritis: a Randomized Clinical Trial. Biol Trace Elem Res. 2024;202(4):1457-67. [PubMed ID: 37477848]. https://doi.org/10.1007/s12011-023-03782-1.
79. Wu YZ, Chen WY, Zeng Y, Ji QL, Yang Y, Guo XL, et al. Inflammation-Responsive Mesoporous Silica Nanoparticles with Synergistic Anti-inflammatory and Joint Protection Effects for Rheumatoid Arthritis Treatment. Pharm Res. 2024;41(7):1493-505. [PubMed ID: 38918308]. https://doi.org/10.1007/s11095-024-03732-z.
80. Kour G, Haq SA, Yadav G, Gupta PN, Ahmed Z. Novel Delivery Systems for Natural Products in Improved Therapy of Rheumatoid Arthritis. Novel Phytopharmaceutical for Management of Disorders. 2024. p. 24-53. https://doi.org/10.1201/9781003292692-2
Published
Abstract Display: 9 
PDF Downloads: 11 PDF Downloads: 8 How to Cite
Issue
Section
Copyright (c) 2026 Pawan Swami, Ajita S. Kesharwani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.